A RETROSPECTIVE OBSERVATIONAL STUDY TO ASSESS THE ROLE OF FUROSEMIDE IN PREVENTION OF BRONCHO-PULMONARY DYSPLASIA IN PRETERM INFANTS(28-32WKS).

Abstract

1. BACKGROUND OF THE STUDY: Bronchopulmonary dysplasia (BPD) is the most common pulmonary morbidity associated with prematurity and pre- mature infants with BPD are at an increased risk of death and severe developmental disability .Despite the devastating impact of BPD on premature infants, there are currently no therapies labeled by the US Food and Drug Administration to prevent BPD. Neonatologists commonly use furosemide as off-label in premature infants. 2. OBJECTIVE: A. To evaluate the role of Furosemide in prevention of Bronchopulmonary Dysplasia in preterm infants. 3. METHODOLOGY: Details of total 350 babies admitted to SNCU and NICU of BMCH with gestational age between 28-32 weeksare included in this study for last 2 years (Nov,2019—Nov 2021). The data regarding exposure to Furosemide are searched retrospectively from medical records of the hospital. 4. RESULTS: Details of total 350 babies are taken in this study and among the total study population 47 babies died within 36 weeks of PMAof any cause . The percentage of BPD was found to be higher in non exposed group which is 43% in comparison to exposed group With 17% and which is statistically signicant(p-0.0028).Odds of furosemide exposure among BPD cases is less than non BPD cases.(OR=0.26).83% babies weaned off th from oxygen/CPAP/ventilator from 7 day to 36 weeks of PMAin exposed group in comparison to non exposed group(57%). 5. CONCLUSIONS: We found that a lesser percentage of Broncho-Pulomonary Dysplasia in the babies exposed to furosemide between birth to 36 weeks of PMA in premature infants. These results provide important preliminary data to support the development of prospective studies to evaluate the safety and efcacy of furosemide for the prevention of BPD in premature infant.